Literature DB >> 35059587

Genetic Counseling, Screening and Risk-Reducing Surgery in Patients with Primary Breast Cancer and Germline BRCA Mutations: Unmet Needs in Low- and Middle-Income Countries.

Hiba A Moukadem1, Ahmad Al Masry1, Rula W Atwani1, Firas Kreidieh1, Lana E Khalil1, Rita Saroufim1, Sarah Daouk1, Iman Abou Dalle1, Nagi S El Saghir1.   

Abstract

OBJECTIVE: Worldwide genetic counseling practices are variable and often not reported in low- and middle-income countries (LMICs). We present the follow-up genetic counseling, breast screening, risk-reducing salpingo-oophorectomy (RRSO) and contralateral prophylactic mastectomy (CPM) in a cohort of study patients with either BRCA pathogenic mutations or BRCA variant of unknown significance (VUS).
MATERIALS AND METHODS: Chart review and phone calls for the collection of information. Out of a cohort of 250 patients, 14 had deleterious mutations and 31 had a VUS, of whom 19 had primary early breast cancer. We collected information about genetic counseling, screening, CPM and RRSO.
RESULTS: Fourteen patients with deleterious mutations (7 BRCA1 and 7 BRCA2) and 19 patients with VUS mutations (20 VUS, 4 BRCA1, 16 BRCA2; 1 patient had both) were surveyed. Of 14 patients with deleterious BRCA mutations, 57.14% (8/14 patients) received genetic counseling from their oncologist. Subsequently 85.71% (12/14) are undergoing mammography screening and 35.71% (5/14) breast screening magnetic resonance imaging (MRI). Furthermore, 50% of them underwent CPM and 57.14% underwent RRSO. Of 19 patients with VUS mutations, 10.5% received genetic counseling from their oncologist; 78.9% were undergoing regular screening mammogram and 31.5% were undergoing breast MRI; one patient underwent CPM and two patients RRSO.
CONCLUSION: Within three years from knowing they have a mutation, 50% of patients with germline BRCA mutations had undergone CPM and 60% RRSO, the majority of them had screening mammography surveillance but only 50% had screening MRI. Follow-up of patients with VUS with mammography was 78% but MRI was only 31%. Lack of MRI surveillance reflects both limited resources and insufficient counseling. Genetic counseling was done by medical oncologists, which reflects a trend in LMIC. Our Data shows the importance of the need for professional genetic counselors and optimal surveillance in Lebanon and other LMICs. ©Copyright 2022 by Turkish Federation of Breast Diseases Associations.

Entities:  

Keywords:  Hereditary breast cancer; VUS mutation; genetic counseling; germline BRCA mutation; risk-reducing salpingo-oophorectomy; screening; contralateral prophylactic mastectomy

Year:  2021        PMID: 35059587      PMCID: PMC8734520          DOI: 10.4274/ejbh.galenos.2021.2021-5-1

Source DB:  PubMed          Journal:  Eur J Breast Health


  41 in total

1.  Genetic Testing for Breast Cancer in the Era of Multigene Panels: Can We Make an Impact on Population Health?

Authors:  Ophira Ginsburg; Paul Brennan
Journal:  J Clin Oncol       Date:  2018-08-21       Impact factor: 44.544

2.  Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award.

Authors:  Mary-Claire King; Ephrat Levy-Lahad; Amnon Lahad
Journal:  JAMA       Date:  2014-09-17       Impact factor: 56.272

3.  A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Authors:  J Mateo; D Chakravarty; R Dienstmann; S Jezdic; A Gonzalez-Perez; N Lopez-Bigas; C K Y Ng; P L Bedard; G Tortora; J-Y Douillard; E M Van Allen; N Schultz; C Swanton; F André; L Pusztai
Journal:  Ann Oncol       Date:  2018-09-01       Impact factor: 32.976

4.  Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.

Authors:  Christoph Engel; Christine Fischer; Silke Zachariae; Karolin Bucksch; Kerstin Rhiem; Jutta Giesecke; Natalie Herold; Barbara Wappenschmidt; Verena Hübbel; Monika Maringa; Simone Reichstein-Gnielinski; Eric Hahnen; Claus R Bartram; Nicola Dikow; Sarah Schott; Dorothee Speiser; Denise Horn; Eva M Fallenberg; Marion Kiechle; Anne S Quante; Anne-Sophie Vesper; Tanja Fehm; Christoph Mundhenke; Norbert Arnold; Elena Leinert; Walter Just; Ulrike Siebers-Renelt; Stefanie Weigel; Andrea Gehrig; Achim Wöckel; Brigitte Schlegelberger; Stefanie Pertschy; Karin Kast; Pauline Wimberger; Susanne Briest; Markus Loeffler; Ulrich Bick; Rita K Schmutzler
Journal:  Int J Cancer       Date:  2019-05-22       Impact factor: 7.396

5.  Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative.

Authors:  Marie E Wood; Pamela Kadlubek; Trang H Pham; Dana S Wollins; Karen H Lu; Jeffrey N Weitzel; Michael N Neuss; Kevin S Hughes
Journal:  J Clin Oncol       Date:  2014-02-03       Impact factor: 44.544

6.  Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.

Authors:  Alexandra J van den Broek; Laura J van 't Veer; Maartje J Hooning; Sten Cornelissen; Annegien Broeks; Emiel J Rutgers; Vincent T H B M Smit; Cees J Cornelisse; Mike van Beek; Maryska L Janssen-Heijnen; Caroline Seynaeve; Pieter J Westenend; Jan J Jobsen; Sabine Siesling; Rob A E M Tollenaar; Flora E van Leeuwen; Marjanka K Schmidt
Journal:  J Clin Oncol       Date:  2015-12-23       Impact factor: 44.544

7.  Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.

Authors:  Rachel Greenup; Adam Buchanan; Wendy Lorizio; Keelia Rhoads; Salina Chan; Tracey Leedom; Robin King; Jane McLennan; Beth Crawford; P Kelly Marcom; E Shelley Hwang
Journal:  Ann Surg Oncol       Date:  2013-08-22       Impact factor: 5.344

8.  Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.

Authors: 
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

Review 9.  Contralateral prophylactic mastectomy: current perspectives.

Authors:  Katharine Yao; Mark Sisco; Isabelle Bedrosian
Journal:  Int J Womens Health       Date:  2016-06-22

Review 10.  A Review of the Hereditary Component of Triple Negative Breast Cancer: High- and Moderate-Penetrance Breast Cancer Genes, Low-Penetrance Loci, and the Role of Nontraditional Genetic Elements.

Authors:  Darrell L Ellsworth; Clesson E Turner; Rachel E Ellsworth
Journal:  J Oncol       Date:  2019-07-09       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.